NCT04091646 - Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

August 18, 2020

Study Completion Date

August 21, 2020

Conditions

Seborrheic Dermatitis

Interventions

DRUG

Roflumilast Foam 0.3%

Roflumilast foam for topical application.

DRUG

Vehicle foam

Vehicle foam for topical application.

Trial Locations (24)

15213

Arcutis Biotherapeutics Clinical Site 27, Pittsburgh

20850

Arcutis Biotherapeutics Clinical Site 28, Rockville

23502

Arcutis Biotherapeutics Clinical Site 17, Norfolk

27262

Arcutis Biotherapeutics Clinical Site 23, High Point

33134

Arcutis Biotherapeutics Clinical Site 42, Coral Gables

33144

Arcutis Biotherapeutics Clinical Site 24, Miami

33613

Arcutis Biotherapeutics Clinical Site 12, Tampa

40217

Arcutis Biotherapeutics Clinical Site 15, Louisville

43209

Arcutis Biotherapeutics Clinical Site 18, Bexley

46168

Arcutis Biotherapeutics Clinical Site 22, Plainfield

48038

Arcutis Biotherapeutics Clinical Site 40, Clinton Township

48202

Arcutis Biotherapeutics Clinical Site 20, Detroit

55432

Arcutis Biotherapeutics Clinical Site 14, Fridley

60008

Arcutis Biotherapeutics Clinical Site 10, Rolling Meadows

76011

Arcutis Biotherapeutics Clinical Site 13, Arlington

77056

Arcutis Biotherapeutics Clinical Site 25, Houston

77845

Arcutis Biotherapeutics Clinical Site 41, College Station

78660

Arcutis Biotherapeutics Clinical Site 26, Pflugerville

78759

Arcutis Biotherapeutics Clinical Site 11, Austin

90404

Arcutis Biotherapeutics Clinical Site 21, Santa Monica

94538

Arcutis Biotherapeutics Clinical Site 19, Fremont

97210

Arcutis Biotherapeutics Clinical Site 29, Portland

L3P 1X2

Arcutis Biotherapeutics Clinical Site 31, Markham

N8W 1E6

Arcutis Biotherapeutics Clinical Site 30, Windsor